Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 1, 2017, Pages

  Walters, Julia Ae ^a   Tang, Joanne Ngie Qing ^a   Poole, Phillippa ^b   Wood Baker, Richard ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; DISEASE EXACERBATION; DRUG EFFICACY; EMBASE; FORCED EXPIRATORY VOLUME; HOSPITAL ADMISSION; HUMAN; INFECTION PREVENTION; MEDLINE; META ANALYSIS; MORTALITY; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STREPTOCOCCUS PNEUMONIA; SYSTEMATIC REVIEW; VACCINATION; VACCINATION REACTION; AGED; CAUSE OF DEATH; COMMUNITY-ACQUIRED INFECTIONS; COMPLICATION; FEMALE; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMONIA, PNEUMOCOCCAL;

AGED; CAUSE OF DEATH; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85011082331     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD001390.pub4     Document Type: Review

References (163)

1. Alfageme I, Reyes N, Vazquez R, Perez J, Munoz, Hernandez M, et al. Clinical efficacy of pneumococcal vaccine in COPD patients. Preliminary results. Chest 2004;126(4 Suppl):837S. [3049808]
2. Alfageme I, Vazquez R, Reyes N, Munoz J, Fernandez A, Hernandez M, et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 2006;61:189-95. [3049809]
3. Davis AL, Aranda C, Christianson L, Schiffman G. Effects of 14-valent pneumococcal capsular polysaccharide vaccine in patients with COPD. Chest 1984;85(Suppl):82-3. [3049811; DOI: 10.1378/chest.85.6_Supplement.82S-a]
4. Davis AL, Aranda CP, Schiffman G, Christianson LC. Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. A pilot study. Chest 1987;92(2):204-12. [3049812]
5. Dransfield MT, Harnden S, Burton RL, Albert RK, Bailey WC, Casaburi R, et al. Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clinical Infectious Diseases 2012;55:e35-44. [3049814]
6. Dransfield MT, Nahm MH, Han MK, Harnden S, Criner GJ, Martinez FJ, et al. Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2009;180(6):499-505. [3049815]
7. NCT00457977 Comparing two pneumococcal vaccines in adults with chronic obstructive pulmonary disease (PNEUMO). https://clinicaltrials.gov/ct2/show/NCT00457977 (accessed 1 August 2016). [3049816]
8. Furumoto A, Ohkusa Y, Chen M, Kawakami K, Masaki H, Sueyasu Y, et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine 2008;26(33):4284-9. [3049818]
9. Kostinov MP, Ryzhov AA, Magarshak OO, Zhirova SN, Protasov AD, Erofeev IuV, et al. [The clinical aspects of efficiency of the prevention of pneumococcal infection with vaccines in chronic obstructive pulmonary disease patients living in the West Siberian Region]. [Russian]. Terapevticheskii Arkhiv 2014;86(3):28-33. [3049820]
10. Leech JA, Gervais A, Ruben FL. Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. Canadian Medical Association Journal 1987;136(4):361-5. [3049822]
11. NCT01381367 PPSV23 pneumococcal vaccine in chronic obstructive pulmonary disease (COPD). https://clinicaltrials.gov/ct2/show/NCT01381367 (accessed 1 August 2016). [3049824]
12. Steentoft J, Konradsen HB, Hilskov J, Giglason G, Andersen JR. Response to pneumococcal vaccine in chronic obstructive lung disease - the effect of ongoing, systemic steroid treatment. Vaccine 2006;24:1408-12. [3049826]
13. Teramoto S, Yamamoto H, Yamaguchi Y, Hanaoka Y, Ishil M, Ouchi Y, et al. Clinical efficacy of anti-pneumococcal vaccination in elderly patients with COPD [Abstract]. American Thoracic Society International Conference; 2007 May 18-23; San Francisco. 2007:A137. [3049828]
14. Trofimov VI, Shaporova NL, Marchenko VN, Smirnova IaA. [Effect of pneumo 23 vaccine administration in patients with chronic obstructive pulmonary disease of intermediate severity]. [Russian]. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii 2010;4:41-4. [3049830]
15. Ya Tseimakh I, Martynenko I, Paraeva S. Prophylactic efficacy of pneumococcal vaccination for chronic obstructive pulmonary disease (COPD) [Abstract]. European Respiratory Journal 2006;28(Suppl 50):178s [P1091]. [3049832]
16. Yilmaz D, Uzaslan E, Ege E. Impact of pneumococcal polysaccharide vaccine on acute exacerbation and quality of life in COPD patients (Abstract). American Journal of Respiratory and Critical Care Medicine 2013;187(Meeting Abstracts):A2182. [3049834]
17. Aboussouan LS. Acute exacerbations of chronic bronchitis: focusing management for optimum results. Postgraduate Medicine 1996;99(4):89-104. [3049836]
18. Austrian R, Douglas RM, Schiffman C. Prevention of pneumococcal pneumonia by vaccination. Transactions of the Association of American Physicians 1976;89:184-94. [3049838]
19. Austrian R. Some observations on the pneumococcus and on the current status of pneumococcal disease and its prevention. Reviews of Infectious Diseases 1981;3(Suppl):S1-17. [3049840]
20. Austrian R. A reassessment of pneumococcal vaccine. New England Journal of Medicine 1984;310:651-3. [3049842]
21. Bacle A, Diot P, Lemarie E. Anti-pneumococci vaccine: justifications and results. Revue de Pneumologie Clinique 1997;53(3):128-37. [3049844]
22. Bentley DW. Pneumococcal vaccine in the institutionalized elderly: review of past and recent studies. Reviews of Infectious Diseases 1981;3(Suppl):S61-70. [3049846]
23. Bolan G, Broome CV, Facklam RR, Plikaytis BD, Fraser DW, Schlech WF. Pneumococcal vaccine efficacy in selected populations in the United States. Annals of Internal Medicine 1986;104:1-6. [3049848]
24. Broome CV. Efficacy of pneumococcal polysaccharide vaccines. Reviews of Infectious Diseases 1981;3(Suppl):S82-8. [3049850]
25. Butler JC, Breiman RF, Campbell JF, et al. Efficacy of the pneumococcal vaccine: Is once enough?. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1992 11-14 Oct; Anaheim. 1992. [3049852]
26. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome C, Facklam RR. Pneumococcal polysaccharide vaccine efficacy. JAMA 1993;270:1826-31. [3049854]
27. Chang YC, Chou YJ, Liu JY, Yeh TF, Huang N. Additive benefits of pneumococcal and influenza vaccines among elderly persons aged 75 years or older in Taiwan-a representative population-based comparative study. Journal of Infection 2012;65(3):231-8. [3049856]
28. Chodosh S. Treatment of acute exacerbations of chronic bronchitis: state of the art. American Journal of Medicine 1991;91(Suppl 6A):87S-91S. [3049858]
29. Christenson B, Lundbergh P, Hedlund J, Ortqvist A. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years of older: a prospective study. Lancet 2001;357(9261):1008-11. [3049860]
30. Dilokthornsakul P, Lee TA. The association between pneumococcal vaccine and thrombocytopenia in elderly patients with chronic obstructive pulmonary disease: a case-crossover study. 30th International Conference on Pharmacoepidemiology and Therapeutic Risk Management; 2014 Oct 24-27; Taipei. 2014. [3049862]
31. Douglas RM, Riley ID. Pneumococcal disease and its prevention with polyvalent pneumococcal polysaccharide vaccines - a review. Australian and New Zealand Journal of Medicine 1979;9:327-38. [3049864]
32. Douglas RM, Miles HB. Vaccination against Streptococcus pneumoniae in childhood: lack of demonstrable benefit in young Australian children. Journal of Infectious Diseases 1984;149(6):861-9. [3049866]
33. Ekwurzel GM, Simmons JS, Dublin LI, Felton LD. Studies on immunizing substances in pneumococci. Public Health Reports 1938;53:1877-93. [3049868]
34. Ewig S, Soler N, Torres A. Chronic obstructive pulmonary disease and infection: from stable patients to pneumonia. Clinical Pulmonary Medicine 1999;6(1):1-8. [3049870]
35. Farr BM, Johnston BL, Cobb DK, Fisch MJ, Germanson TP, Adal KA. Preventing pneumococcal bacteremia in patients at risk. Archives of Internal Medicine 1995;155:2336-40. [3049872]
36. Fedson D, Henrichsen J, Makela H, Austrian R. Immunization of elderly people with polyvalent pneumococcal vaccine. Infection 1989;617(6):437-41. [3049874]
37. Fedson DS, Shapiro ED, LaForce FM, Mufson MA, Musher DM, Spika JS, et al. Pneumococcal vaccine after 15 years of use. Another view. Archives of Internal Medicine 1994;154(22):2531-5. [3049876]
38. Fedson DS. The clinical effectiveness of pneumococcal vaccination: a brief review. Vaccine 1999;17:S85-90. [3049878]
39. Felton LD, Ekwurtzel GM, Simmons JS, Dublin LI. Studies on immunizing substances in pneumococci. Public Health Reports 1938;53:1877. [3049880]
40. Ferguson GT, Cherniack RM. Management of chronic obstructive pulmonary disease. New England Journal of Medicine 1993;328(17):1017-22. [3049882]
41. Filice GA. Pneumoccal vaccines and public health policy. Archives of Internal Medicine 1990;150:1373-5. [3049884]
42. Fine MJ, Smith MA, Carson CA, Meffe F, Snakey SS, Weissfeld LA, et al. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Archives of Internal Medicine 1994;154(23):2666-77. [3049886]
43. Forrester HL, Jahnigen DW, LaForce FM. Inefficacy of pneumococcal vaccine in a high-risk population. American Journal of Medicine 1987;83(3):425-30. [3049888]
44. Foschino BMP, Resta O, Cassano A, Altieri A, Guido P, Piti A, et al. Infectious exacerbations of chronic pulmonary diseases. Therapeutic effectiveness of immunomodulants [Riacutizzazioni delle broncopneumopatie croniche]. Minerva Pneumologica 1995;43(2):39-44. [3049890]
45. Gable CB, Holzer SS, Engelhart L, Friedman RB, Smeltz F, Schroeder D, et al. Pneumococcal vaccine: efficacy and associated cost savings. JAMA 1990;264:2910-5. [3049892]
46. Gaillat J, Zmirou D, Mallaret MR, Rouhan D, Stahl JP, Delormas P, et al. Clinical trial of an antipneumococcal vaccine in elderly subjects living in institutions [Essai clinique du vaccin antipneumococcique chez des personnes agées vivant en institution]. Revue d'Epidemiologie et de Sante Publique 1985;33(6):437-44. [3049894]
47. Gaillat J. Should patients with chronic obstructive pulmonary disease be vaccinated against pneumococcal diseases?. Expert Review of Respiratory Medicine 2009;3(6):585-96. [3049896]
48. Gardner P, Schaffner W. Immunization of adults. New England Journal of Medicine 1993;328(17):1252-8. [3049898]
49. Greenberg RN, Gurtman A, Frenck RW, Strout C, Jansen KU, Trammel J, et al. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60-64 years of age. Vaccine 2014;32(20):2364-74. [3049900]
50. Gross NJ. The COPD pipeline VII. COPD 2010;7(6):438-40. [3049902]
51. Hak E, Van Essen GA, Buskens E, Stalman W, de Melker RA. Is immunising all patients with chronic lung disease in the community against influenza cost effective? Evidence from a general practice based clinical prospective cohort study in Utrecht, The Netherlands. Journal of Epidemiology and Community Health 1998;52(2):120-5. [3049904]
52. Halasa J, Halasa M, Wojciechowska W, Podkowinska I, Kucharska E. Clinical efficacy of autovaccine in the treatment of infectious nonatopic asthma and COPD - double blind placebo controlled trial [Ocena efektow leczenia autoszczepionka astmy nieatopowej infekcyjnej i POChP - badanie z zastosowaniem podwojnie slepej proby z placebo]. Alergia Astma Immunologia 2001;6(2):109-13. [3049906]
53. Han MK, Martinez FJ. Pharmacotherapeutic approaches to preventing acute exacerbations of chronic obstructive pulmonary disease. Proceedings of the American Thoracic Society 2011;8(4):356-62. [3049908]
54. Hilleman MR, Carlson AJ Jr, McLean AA, Vella PP, Weibel RE, Woodhour AF. Streptococcus pneumoniae polysaccharide vaccine: age and dose responses, safety, persistence of antibody, revaccination, and simultaneous administration of pneumococcal and influenza vaccines. Reviews of Infectious Diseases 1981;3(Suppl):S31-42. [3049910]
55. Hirschmann JV, Lipsky BA. Pneumococcal vaccine in the United States: a critical analysis. JAMA 1981;246:1428-32. [3049912]
56. Hirschmann JF. The pneumococcal vaccine after 15 years of use. Archives of Internal Medicine 1994;154:373-7. [3049914]
57. Horwood F, Macfarlane J. Pneumococcal and influenza vaccination: current situation and future prospects. Thorax 2002;57(Suppl II):ii24-ii30. [3049916]
58. Hughes JM, Dransfield MT. Predictors of colonisation of pneumococcus in patients with COPD (Abstract). http://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2011.183.1_MeetingAbstracts.A4565 (accessed 1 August 2016). [3049918]
59. Hung IF, Leung AY, Chu DW, Leung D, Cheung T, Chan CK, et al. Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination: a prospective cohort study. Clinical Infectious Diseases 2010;51(9):1007-16. [3049920]
60. Jackson L, Neuzil K, Yu O, Benson P, Barlow W, Adams A, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. New England Journal of Medicine 2003;348(18):1747-55. [3049922]
61. Jimenez-Garcia R, Arinez-Fernandez MC, Hernandez-Barrera V, Garcia-Carballo MM, de Miguel AG, Carrasco-Garrido P. Compliance with influenza and pneumococcal vaccination among patients with chronic obstructive pulmonary disease consulting their medical practitioners in Catalonia, Spain. Journal of Infection 2007;54(1):65-74. [3049924]
62. Jonsson S, Vidarsson G, Valdimarsson H, Schiffman G, Schneerson R, Jonsdottir I. Vaccination of COPD patients with a pneumococcus type 6B tetanus toxoid conjugate vaccine. European Respiratory Journal 2002;20(4):813-8. [3049926]
63. Kaiser AB, Schaffner W. Prospectus: the prevention of bacteremic pneumococcal pneumonia. A conservative appraisal of vaccine intervention. JAMA 1974;230(3):404-8. [3049928]
64. Kaufman P. Studies on old age pneumonia II. Prophylactic effect of pneumococcus polysaccharide against pneumonia. Archives of Internal Medicine 1941;67:304-19. [3049930]
65. Kaufman P, Kaeffely A, Klingst SK, O'Brien C, Stein H. Pneumonia in old age: active immunization against pneumonia with pneumococcus polysaccharide: results of a six-year study. Archives of Internal Medicine 1947;79:518-31. [3049932]
66. Klastersky J, Mommen P, Cantraine F, Safary A. Placebo controlled pneumococcal immunisation in patients with bronchogenic carcinoma. European Journal of Cancer and Clinical Oncology 1986;22:807-13. [3049934]
67. Klein RS, Adachi N. Pneumococcal vaccine in the hospital. Improved use and implications for high-risk patients. Archives of Internal Medicine 1983;143(10):1878-81. [3049936]
68. Koivula I, Sten M, Leinonen M, Makela PH. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. American Journal of Medine 1997;103:281-90. [3049938]
69. Kraus C, Fischer S, Ansorg R, Huttemann U. Pneumococcal antibodies (IgG, IgM) in patients with chronic obstructive lung disease 3 years after pneumococcal vaccination. Medical Microbiology and Immunology 1985;174(1):51-8. [3049940]
70. LaForce LM. Pneumococcal vaccine. Seminars in Respiratory Infections 1989;4(4):293-8. [3049942]
71. Lai CC, Lee LN, Yu CJ, Hsueh PR, Yang PC, Kuo SH, et al. Antibody responses to pneumococcal polysaccharide vaccine in Taiwanese patients with chronic obstructive pulmonary disease. Journal of the Formosan Medical Association 2007;106(3):196-203. [3049944]
72. Landesman SH, Smith PM, Schiffman G. Pneumococcal vaccine in elderly patients with COPD. Chest 1983;84:433-5. [3049946]
73. Larsson L. Use of antibiotics, antioxidants, mucolytics and vaccines in the therapy of chronic obstructive pulmonary disease. European Respiratory Monograph 1998;3(7):163-8. [3049948]
74. Lee TA, Weaver FM, Weiss KB. Impact of pneumococcal vaccination on pneumonia rates in patients with COPD and asthma. Journal of General Internal Medicine 2007;22(1):62-7. [3049950]
75. Leophonte P, Neukirch F. Anti-pneumococci vaccination: role and indications in the prevention of community acquired infections of the lower respiratory tract. Medecine et Maladies Infectieuses 2001;31(4):181-94. [3049952]
76. MacIntyre CR, Egerton T, McCaughey M, Parrino J, Campbell BV, Su SC, et al. Concomitant administration of zoster and pneumococcal vaccines in adults >60 years old. Human Vaccines 2010;6(11):894-902. [3049954]
77. MacLeod CM, Hodges RG, Heidelberger M, Bern Hard NG. Prevention of pneumococcal pneumonia by immunisation with specific capsular polysaccharide. Journal of Experimental Medicine 1945;82:445-65. [3049956]
78. Madison JM, Irwin RS. Chronic obstructive pulmonary disease. Lancet 1998;352(9126):467-73. [3049958]
79. Meyer P, Menzel M, Muellinger B, Weber N, Haeussinger K, Ziegler-Heitbrock L. Inhalative vaccination with pneumococcal polysaccharide in patients with chronic obstructive pulmonary disease. Vaccine 2006;24(31-32):5832-8. [3049960]
80. Monso E. Vaccination and antioxidant therapy [Vacunacion y tratamiento antioxidante]. Archivos de Bronconeumologia 2003;39(Suppl 3):31-3. [3049962]
81. Nichol KL, Baken L, Wuorenma J, Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Archives of Internal Medicine 1999;159(20):2437-42. [3049964]
82. Ochoa-Gondar O, Vila-Corcoles A, Ansa X, Rodriguez-Blanco T, Salsench E, de Diego C, et al. Effectiveness of pneumococcal vaccination in older adults with chronic respiratory diseases: results of the EVAN-65 study. Vaccine 2008;26(16):1955-62. [3049966]
83. Ochoa-Gondar O, Vila-Corcoles A, de Diego C, Arija V, Maxenchs M, Grive M, et al. The burden of community-acquired pneumonia in the elderly: the Spanish EVAN-65 Study. BMC Public Health 2008;8(1):222. [4767197]
84. Orcel B, Delclaux B, Baud M, Derenne JP. Oral immunization with bacterial extracts for protection against acute bronchitis in elderly institutionalized patients with chronic bronchitis. European Respiratory Journal 1994;7(3):446-52. [3049968]
85. Ortqvist A, Hedlund J, Burman LA, Elbel E, Hofer M, Leinonen M, et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet 1998;351(9100):399-403. [3049970]
86. Patrick KM, Woolley FR. A cost-benefit analysis of immunisation of pneumococcal pneumonia. JAMA 1981;245:473-7. [3049972]
87. Preheim L, Rytel M. Pneumococcal infection after vaccination. Lancet 1978; Vol. 2:1317. [3049974]
88. Ricci R, Palmero C, Bazurro G, Riccio AM, Garelli V, Di Marco E, et al. The administration of a polyvalent mechanical bacterial lysate in elderly patients with COPD results in serological signs of an efficient immune response associated with a reduced number of acute episodes. Pulmonary Pharmacology & Therapeutics 2014;27(1):109-13. [3049976]
89. Riley RD, Tarr PI, Andrews M. Immunisation with a polyvalent pneumococcal vaccine: reduction of adult respiratory mortality in a New Guinea Highlands community. Lancet 1977;1:1338-41. [3049978]
90. Rochemaure J, Lehert PH, Sauvaget J, Robillard M, Betbeder-Matibet A. Reduction with an immunomodulator of the infection rate in chronic bronchitis [Reduction par un immunomodulateur de taux d'infections respiratoires dans la bronchite chronique]. Revue de Pneumologie Clinique 1988;44(1):43-7. [3049980]
91. Saag KG, Doebbeling BN, Rohrer JE, Kolluri S, Peterson R, Hermann ME, et al. Variation in tertiary prevention and health service utilization among the elderly. The role of urban-rural residence and supplemental insurance. Medical Care 1998;36(7):965-76. [3049982]
92. Schenkein JG, Nahm MH, Dransfield MT. Pneumococcal vaccination for patients with COPD: current practice and future directions. [Review] [53 refs]. Chest 2008;133(3):767-74. [3049984]
93. Schnelle H, Eeagan TL, Gulsvik A, Nielsen R. Predictors of COPD exacerbation in hospital patients, population based cases and controls. American Journal of Respiratory and Critical Care Medicine 2010;A41:A1507. [3049986]
94. Schwartz JS. Pneumococcal vaccine: clinical efficacy and effectiveness. Annals of Internal Medicine 1982;96:208-20. [3049988]
95. Sehatzadeh S. Influenza and pneumococcal vaccinations for patients with chronic obstructive pulmonary disease (COPD): an evidence-based review. Ontario Health Technology Assessment Series 2012;12(3):1-64. [3049990]
96. Shapiro ED, Clemens JD. A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections. Annals of Internal Medicine 1984;101:325-30. [3049992]
97. Shapiro ED. Pneumococcal vaccine failure. New England Journal of Medicine 1987;316(20):1272-3. [3049994]
98. Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margollis A, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. New England Journal of Medicine 1991;323:1453-60. [3049996]
99. Sheikh A. Evidence-based problem solving. What is the efficacy of pneumococcal vaccination in people with asthma?. Asthma in General Practice 1999;7(2):21-2. [3049998]
100. Simberkoff MS, Cross AP, Al-Ibrahim M, Baltch AL, Geiseler PJ, Nadler J, et al. Efficacy of pneumococcal vaccine in high risk-patients. Results of a Veterans Administration cooperative study. New England Journal of Medicine 1986;315(21):1318-27. [3050000]
101. Simberkoff MS. Pneumococcal vaccine in the prevention of community-acquired pneumonia: a skeptical view of cost-effectiveness. Seminars in Respiratory Infection 1993;8(4):294-9. [3050002]
102. Sims RV, Steinmann WC, McConville JH, King LR, Zwick WC, Schwartz JS. The clinical effectiveness of pneumococcal vaccine in the elderly. Annals of Internal Medicine 1988;108(5):653-7. [3050004]
103. Sisk JE, Riegelman RK. Cost effectiveness of vaccination against pneumococcal pneumonia: an update. Annals of Internal Medicine 1986;104:79-86. [3050006]
104. Smit P, Oberholzer D, Hayden-Smith S, Koornhof HJ, Hilleman MR. Protective efficacy of pneumococcal polysaccharide vaccines. JAMA 1977;238:2613-6. [3050008]
105. Sumitani M, Tochino Y, Kamimori T, Fujiwara H, Fujikawa T. Additive inoculation influenza vaccine and 23-valent pneumococcal polysaccharide vaccine to prevent lower respiratory tract infections in chronic respiratory disease patients. Internal Medicine 2008;47(13):1189-97. [3050010]
106. Van Amptin JMA, Bouter KP, Diepersloot RJA, Overbeek BP, Netten P, Erkelens DW. Pneumococcal bacteraemia: incidence, outcome and predisposing factors. European Journal of Internal Medicine 1998;9:145-50. [3050012]
107. Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, Gutierrez-Perez A, Vila-Rovira A. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in patients with chronic pulmonary diseases: a matched case-control study. Human Vaccines & Immunotherapeutics 2012;8(5):639-44. [3050014]
108. Watanuki Y, Miyazawa N, Kudo M, Inoue S, Goto H, Kaneko T, et al. Effects of pneumococcal vaccine in patients with chronic respiratory disease [Abstract]. European Respiratory Journal 2007;30(Suppl 51):224s [E1368]. [3050016]
109. Wencker M, Konietzko N. Alpha-1-protease inhibitor deficiency and pulmonary emphysema as viewed by pulmonary specialists in private practice [Alpha-1-Proeinaseninhibitor-Mangel und Lungenemphysem aus der Sicht des niedergelassenen Pneumologen]. Atemwegs-und Lungenkrankheiten 1999;25(2):89-95. [3050018]
110. Wenzel P, Craven R, Davies J, Hendley J, Hamory B, Gwaltney J. Field trial of an inactivated Mycoplasma pneumoniae vaccine. Journal of Infectious Diseases 1976;134(6):571-6. [3050020]
111. World Health Organization. Pneumococcal vaccines: World Health Organization position paper. Weekly Epidemiological Record 1999;74(23):177-83. [3050022]
112. World Health Organization. Pneumococcal vaccines: World Health Organization position paper. Canada Communicable Disease Report 1999;25(17):150-1. [3050024]
113. Wiebel RE, Vella PP, McLean AA. Studies in human subjects of polyvalent pneumococcal vaccines. Proceedings of the Society for Experimental Biology and Medicine 1977;156:144-50. [3050026]
114. Willems JS, Sanders CR, Riddiough MA. Cost effectiveness of vaccination against pneumococcal pneumonia. New England Journal of Medicine 1980;303:553-9. [3050028]
115. Williams JH, Moser KM. Pneumococcal vaccine and patients with chronic lung disease. Annals of Internal Medicine 1986;104(1):106-9. [3050030]
116. Wright AE, Morgan WP, Colebrook L, Dodgson RW. Prophylactic inoculation against pneumococcus infections. Lancet 1914;183(4714):87-95. [3050032]
117. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Annals of Internal Medicine 1987;106(2):196-204.
118. Bogaert D, Van der Valk P, Ramdin R, Sluijter M, Monninkhof E, Hendrix R, et al. Host-pathogen interaction during pneumococcal infection in patients with chronic obstructive pulmonary disease. Infection and Immunity 2004;72(2):818-23.
119. Bonten MJM, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. New England Journal of Medicine 2015;372:1114-25.
120. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, et al. International variation in the prevalence of COPD (the BOLD study): a population-based prevalence study. The Lancet 2007;370(9589):741-50.
121. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. European Respiratory Journal 2003;21:46s-53s.
122. Burgess L, Southern KW. Pneumococcal vaccines for cystic fibrosis. Cochrane Database of Systematic Reviews 2014, Issue 8. [DOI: 10.1002/14651858.CD008865.pub3]
123. Chalmers JD, Campling J, Dicker A, Woodhead M, Madhava H. A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults. BMC Pulmonary Medicine 2016;16:77.
124. Chang CC, Singleton RJ, Morris PS, Chang AB. Pneumococcal vaccines for children and adults with bronchiectasis. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD006316.pub3]
125. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
126. COPD Guidelines Steering Committee. The COPD-X plan: Australian and New Zealand guidelines for the management of chronic obstructive pulmonary disease, March 2016. http://www.copdx.org.au/ (accessed 2 July 2016).
127. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57(10):847-52.
128. Donaldson GC, Wilkinson TMA, Hurst JR, Perera WR, Wedzicha JA. Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2005;171:446-52.
129. European Respiratory Society. Immunisation against respiratory diseases. http://www.erswhitebook.org/chapters/immunisation-against-respiratory-diseases/streptococcus-pneumoniae/ (accessed 25 November 2014).
130. File TM Jr. Community-acquired pneumonia. The Lancet 2003;362(9400):1991-2001.
131. File TM Jr, Monte SV, Schentag JJ, Paladino JA, Klugman KP, Lavin B, et al. A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community-acquired pneumonia: roles for underlying lung disease and the pharmacokinetics/pharmacodynamics of the antibiotic. International Journal of Antimicrobial Agents 2009;33(1):58-64.
132. GOLD Executive Committee. Global strategy for diagnosis, management, and prevention of COPD. http://www.goldcopd.com (accessed 2 July 2016).
133. Groenewegen K, Schols A, Wouters EFM. Prognosis after hospitalization for acute exacerbations of COPD. European Respiratory Journal 2001;8(Suppl 33):209s.
134. Hak E, Hoes AW, Nordin JIM, Nichol KL. Benefits of influenza vaccine in US elderly - appreciating issues of confounding bias and precision. International Journal of Epidemiology 2006;35(3):800-2.
135. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. British Medical Journal 2003;327(7414):557-60.
136. Jackson LA, Jackson ML, Nelson JC, Neuzil KM, Weiss NS. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. International Journal of Epidemiology 2006;35(2):337-44.
137. Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2014;3:CD010115.pub2.
138. Leidy NK, Wilcox TK, Jones PW, Murray L, Winnette R, Howard K, et al. Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): a patient-reported outcome (PRO) measure. Value in Health 2010;13(8):965-75.
139. Lieberman D, Gelfer Y, Varshavsky R, Dvoskin B, Leinonen M, Friedman MG. Pneumonic vs nonpneumonic acute exacerbations of COPD. Chest 2002;122(4):1264-70.
140. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clinical Infectious Diseases 2007;44(Suppl 2):S27-72.
141. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database of Systematic Reviews 2013, Issue 1. [DOI: 10.1002/14651858.CD000422.pub3]
142. Molinos L, Clemente MG, Miranda B, Alvarez C, del Busto B, Cocina BR, et al. Community-acquired pneumonia in patients with and without chronic obstructive pulmonary disease. Journal of Infection 2009;58(6):417-24.
143. Moseley AM, Dransfield MT. Pneumococcal vaccination in adults: recent evidence from clinical trials and observational studies. Clinical Investigation 2013;3(9):887-97.
144. NHMRC: Australian Technical Advisory Group on Immunisation. The Australian Immunisation Handbook. 10th Edition. Canberra: Australian Government Department of Health, 2013.
145. National Institute of Clinical Excellence. COPD: national clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004;59(Suppl 1):181-272.
146. National Clinical Guideline Centre. Chronic Obstructive Pulmonary Disease: Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary Care. London: National Clinical Guideline Centre, 2010. www.nice.org.uk/guidance/cg101.
147. Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. American Journal of Respiratory & Critical Care Medicine 2006;173(10):1114-21.
148. Patel IS, Seemungal TAR, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha JA. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 2002;57:759-64.
149. Postma DF, van Werkhoven CH, Huijts SM, Bolkenbaas M, Oosterheert JJ, Bonten MJ. New trends in the prevention and management of community-acquired pneumonia. Netherlands Journal of Medicine 2012;70(8):337-48.
150. Restrepo MI, Mortensen EM, Pugh JA, Anzueto A. COPD is associated with increased mortality in patients with community-acquired pneumonia. European Respiratory Journal 2006;28(2):346-51.
151. The Nordic Cochrane Centre. Review Manager (RevMan). Version 5.3. Copenhagen: The Cochrane Collaboration, 2014.
152. Rodrigo C, Bewick T, Sheppard C, Greenwood S, McKeever TM, Trotter CL, et al. Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia. European Respiratory Journal 2015;45(6):1632-41.
153. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000;117(90052):398S-401S.
154. Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 1998;157:1418-22.
155. Seemungal T, Donaldson G, Bhowmik A, Jefries D, Wedizicha J. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2000;161(5):1608-13.
156. Sethi S, Evans N, Grant BJB, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. New England Journal of Medicine 2002;347(7):465-71.
157. Sheikh A, Alves B, Dhami S. Pneumococcal vaccine for asthma. Cochrane Database of Systematic Reviews 2002, Issue 1. [DOI: 10.1002/14651858.CD002165]
158. Soler-Cataluna JJ, Martinnez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005;60(11):925-31.
159. Torres A, Dorca J, Zalacain R, Bello S, El-Ebiary M, Molinos L, et al. Community-acquired pneumonia in chronic obstructive pulmonary disease: a Spanish multicenter study. American Journal of Respiratory and Critical Care Medicine 1996;154(5):1456-61.
160. Wedzicha JA, Donaldson GC. Exacerbations of chronic obstructive pulmonary disease. Respiratory Care 2003;48(12):1204-15.
161. Welte T, Kohnlein T. Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ Network. Seminars in Respiratory and Critical Care Medicine 2009;30(2):127-35.
162. World Health Organization. WHO position paper on pneumococcal vaccines 2012. http://www.who.int/immunization/position_papers/PP_pneumococcal_April_2012_summary.pdf (accessed 8 April 2014).
163. World Health Organization. Global health estimates - years 2000-2011. http://www.who.int/healthinfo/global_burden_disease/en/ (accessed 8 April 2014).